Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.78 +0.52 (+1.07%)

Streaming Delayed Price Updated: 11:57 AM EDT, Jul 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗

July 06, 2026

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

Via MarketBeat

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗

July 06, 2026

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Via The Motley Fool

Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) ↗

July 06, 2026

Lilly offers investors safety and growth.

Via The Motley Fool

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗

July 05, 2026

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Via The Motley Fool

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying ↗

July 04, 2026

The stock is known to soar on good news.

Via The Motley Fool

Here's Why Viking Therapeutics Stock Surged Higher in June ↗

July 03, 2026

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

Via The Motley Fool

2 Top Growth Stocks to Buy Right Now Without Hesitation ↗

June 29, 2026

These stocks are no-brainer buys.

Via The Motley Fool

Topics Economy

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now ↗

June 27, 2026

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Via The Motley Fool

Topics Intellectual Property

Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly? ↗

June 26, 2026

Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead.

Via The Motley Fool

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? ↗

June 25, 2026

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

Via The Motley Fool

The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch ↗

June 25, 2026

These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI.

Via The Motley Fool

Topics Artificial Intelligence

2 Underrated Weight Loss Stocks to Buy and Hold ↗

June 23, 2026

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Via The Motley Fool

Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk ↗

June 22, 2026

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

Via The Motley Fool

Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock? ↗

June 20, 2026

Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.

Via The Motley Fool

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend ↗

June 20, 2026

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

Via MarketBeat

Topics ETFs

Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock? ↗

June 16, 2026

These two healthcare leaders have a long history of competing against one another.

Via The Motley Fool

3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗

June 16, 2026

All three could become highly prominent biotech companies within 10 years.

Via The Motley Fool

3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow ↗

June 14, 2026

Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.

Via The Motley Fool

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About ↗

June 12, 2026

The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Via The Motley Fool

Is Viking Therapeutics Stock Going to $100? ↗

June 12, 2026

Viking stock is known for soaring after positive news.

Via The Motley Fool

Why Pfizer Stock Popped Today ↗

June 11, 2026

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Via The Motley Fool

80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case? ↗

June 07, 2026

Novo Nordisk could maintain this latest early-mover advantage longer than you think.

Via The Motley Fool

Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now? ↗

June 06, 2026

Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.

Via The Motley Fool

Topics Intellectual Property

CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors ↗

June 05, 2026

It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.

Via The Motley Fool

Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success ↗

June 04, 2026

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.

Via The Motley Fool

Topics Intellectual Property

Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better ↗

June 03, 2026

Can any company pose a serious challenge to Eli Lilly in the weight-loss market?

Via The Motley Fool

Here's What I Think Is Really Going on With Novo Nordisk Stock ↗

June 03, 2026

There is light at the end of the tunnel.

Via The Motley Fool

Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗

June 03, 2026

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Via The Motley Fool

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage ↗

June 02, 2026

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.